Pmv Pharmaceuticals Inc (NASDAQ: PMVP) — Perfil da empresa, notícias e dados financeiros
PMV Pharmaceuticals develops precision medicines targeting cancer treatment by leveraging p53.

Pmv Pharmaceuticals Inc
PMV Pharmaceuticals (NASDAQ:PMVP) is dedicated to the discovery and development of precision medicines for cancer treatment. With a focus on leveraging the power of p53, the body's natural tumor suppressor protein, Pmv aims to unlock new therapeutic options for patients. The company's projects primarily revolve around creating small molecule therapies designed to restore the normal function of mutant p53 proteins. Their objective is to advance these groundbreaking treatments through clinical trials with the ultimate goal of offering new hope to individuals battling cancer. This pursuit not only reflects Pmv's commitment to innovation in oncology but also underscores their dedication to improving patient outcomes through scientific excellence.
Resumo
Operações
Produtos e/ou serviços de Pmv Pharmaceuticals Inc
- PC14586, a small molecule reactivator of p53 Y220C mutant.
- Research in targeted therapies for cancer with p53 mutations.
- Pipeline development for small molecule therapeutics in oncology.
- Advancements in precision medicine for cancer treatment.
- Collaborations with leading biotech firms to enhance drug discovery.
- Services in drug development and clinical trial support for cancer therapies.
equipe executiva do Pmv Pharmaceuticals Inc
- David H. MackCo-Founder, CEO, President & Director
- Arnold J. LevineCo-Founder, Independent Director & Member of Scientific Advisory Board
- Robert TicktinGeneral Counsel, COO & Company Secretary
- Deepika JalotaChief Development Officer
- Michael CarulliCFO & Principal Financial & Accounting Officer
- Tim SmithSenior VP and Head of Corporate Development & Investor Relations
Últimas notícias sobre a Pmv Pharmaceuticals Inc
Principais indicadores financeiros
Resultados divulgados pela Pmv Pharmaceuticals Inc, em USD.
- Cap. de mercado
- 104,2 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.4
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -86,2 mi | -77,7 mi | |
| 0 | -85,4 mi | -58,7 mi | |
| 0 | -80,1 mi | -69 mi | |
| 0 | -77 mi | -73,3 mi |